{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:01:27Z","timestamp":1792796487615,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prnil.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:21:33Z","timestamp":1739503293000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pelvic lymph node management in prostate cancer: a narrative review"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-7657","authenticated-orcid":false,"given":"Bryan","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-6398","authenticated-orcid":false,"given":"Vincent","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Xue","family":"Hoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Guang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-8439","authenticated-orcid":false,"given":"Jeffrey","family":"Tuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-7567","authenticated-orcid":false,"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prnil.2025.02.001_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16632","article-title":"Selective treatment de-escalation in advanced prostate cancer: have we come full circle?","author":"Chong","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.02.001_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1226366","article-title":"Role of lymphatic invasion in predicting biochemical recurrence after radical prostatectomy","volume":"13","author":"Chung","year":"2023","journal-title":"Front Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.prnil.2025.02.001_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-5347(17)38748-7","article-title":"Prognostic significance of lymph nodal metastases in prostate cancer","volume":"142","author":"Gervasi","year":"1989","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","article-title":"Risk of prostate carcinoma death in patients with lymph node metastasis","volume":"91","author":"Cheng","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.prnil.2025.02.001_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.prnil.2025.02.001_bib7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1148\/rg.311105072","article-title":"Pathways of lymphatic spread in male urogenital pelvic malignancies","volume":"31","author":"Pa\u00f1o","year":"2011","journal-title":"Radiographics"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2012.06.057","article-title":"Mapping of pelvic lymph node metastases in prostate cancer","volume":"63","author":"Joniau","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.02.001_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fsurg.2018.00052","article-title":"Difference in frequency and distribution of nodal metastases between intermediate and high risk prostate cancer patients: results of a superextended pelvic lymph node dissection","volume":"5","author":"Roscigno","year":"2018","journal-title":"Front Surg"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12957-024-03344-2","article-title":"The role and controversy of pelvic lymph node dissection in prostate cancer treatment: a focused review","volume":"22","author":"Dong","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000500330","article-title":"Lymph nodes invasion of Marcille's fossa associates with high metastatic load in prostate cancer patients undergoing extended pelvic lymph node dissection: the role of \"marcillectomy\"","volume":"103","author":"Porcaro","year":"2019","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.prnil.2025.02.001_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/pros.23949","article-title":"Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: histopathological and molecular analyses","volume":"80","author":"Bando","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.prnil.2025.02.001_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2016.02.014","article-title":"Current status of lymph node imaging in bladder and prostate cancer","volume":"96","author":"Kiss","year":"2016","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.prnil.2025.02.001_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.euf.2017.09.003","article-title":"Using imaging to predict treatment response in genitourinary malignancies","volume":"4","author":"Lebastchi","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.prnil.2025.02.001_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prnil.2025.02.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.110110","article-title":"Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer","volume":"147","author":"Valentin","year":"2022","journal-title":"Eur J Radiol"},{"issue":"11","key":"10.1016\/j.prnil.2025.02.001_bib19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JU.0000000000000531","article-title":"Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography\/computerized tomography for primary staging of prostate cancer","volume":"203","author":"van Kalmthout","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"(68)Ga-Labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13014-020-01675-4","article-title":"Can (68)Ga-prostate specific membrane antigen positron emission tomography\/computerized tomography provide an accurate lymph node staging for patients with medium\/high risk prostate cancer? A diagnostic meta-analysis","volume":"15","author":"Peng","year":"2020","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.prnil.2025.02.001_bib23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis","volume":"53","author":"Jeet","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13014-017-0902-0","article-title":"Detection level and pattern of positive lesions using PSMA PET\/CT for staging prior to radiation therapy","volume":"12","author":"Schmidt-Hegemann","year":"2017","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.24627","article-title":"The diagnostic accuracy of (68) Ga-PSMA-PET\/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: a single-center cohort analysis","volume":"84","author":"Rajwa","year":"2024","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","article-title":"Good practices for (68)Ga radiopharmaceutical production","volume":"7","author":"Nelson","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"(18)F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics"},{"issue":"1101","key":"10.1016\/j.prnil.2025.02.001_bib29","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190193","article-title":"Diagnostic accuracy of (F)18 flucholine PET\/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis","volume":"92","author":"Kim","year":"2019","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1016\/j.prnil.2025.02.001_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CM9.0000000000002850","article-title":"18 F-prostate specific membrane antigen positron emission tomography\/computerized tomography for lymph node staging in medium\/high risk prostate cancer: a systematic review and meta-analysis","volume":"137","author":"Lv","year":"2024","journal-title":"Chin Med J (Engl)."},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","article-title":"Meta-analysis of 18 F-PSMA-1007 PET\/CT, 18 F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer","volume":"23","author":"Yu","year":"2023","journal-title":"Cancer Imaging"},{"issue":"17","key":"10.1016\/j.prnil.2025.02.001_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175064","article-title":"Primary staging of prostate cancer patients with [(18)F]PSMA-1007 PET\/CT compared with [(68)Ga]Ga-PSMA-11 PET\/CT","volume":"11","author":"Hoffmann","year":"2022","journal-title":"J Clin Med"},{"issue":"10231","key":"10.1016\/j.prnil.2025.02.001_bib34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.prnil.2025.02.001_bib36","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1007\/s00330-023-10436-2","article-title":"Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis","volume":"34","author":"Ma","year":"2024","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.euo.2022.03.003","volume":"5","author":"Chen","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bju.13600","article-title":"Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission\/computed tomography for primary staging in prostate cancer","volume":"119","author":"Murphy","year":"2017","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with (18)F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.02.001_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2021.09.006","volume":"33","author":"Ling","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bju.15134","article-title":"Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET\/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer","volume":"127","author":"Franklin","year":"2021","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.prnil.2025.02.001_bib43","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.21037\/tau-20-729","article-title":"A narrative review of pelvic lymph node dissection in prostate cancer","volume":"9","author":"Cheung","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib45","article-title":"Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.prnil.2025.02.001_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2022.05.016","article-title":"Pelvic lymph node dissection at the time of radical prostatectomy: extended, of course","volume":"44","author":"Gandaglia","year":"2022","journal-title":"Eur Urol Open Sci."},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.prnil.2024.03.002","article-title":"Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer","volume":"12","author":"Morizane","year":"2024","journal-title":"Prostate Int"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prnil.2022.12.005","article-title":"Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates","volume":"11","author":"Nagaya","year":"2023","journal-title":"Prostate Int"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.prnil.2024.07.002","article-title":"Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study","volume":"12","author":"Washino","year":"2024","journal-title":"Prostate Int"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.prnil.2025.02.001_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11934-017-0696-5","article-title":"Therapeutic value of standard versus extended pelvic lymph node dissection during radical prostatectomy for high-risk prostate cancer","volume":"18","author":"Colicchia","year":"2017","journal-title":"Curr Urol Rep"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12957-024-03344-2","article-title":"The role and controversy of pelvic lymph node dissection in prostate cancer treatment: a focused review","volume":"22","author":"Dong","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"5-6","key":"10.1016\/j.prnil.2025.02.001_bib53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000514439","article-title":"High BMI, aggressive tumours and long console time are independent predictive factors for symptomatic lymphocele formation after robot-assisted radical prostatectomy and pelvic lymph node dissection","volume":"105","author":"Go\u00dfler","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.prnil.2025.02.001_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13014-015-0470-0","article-title":"Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis","volume":"10","author":"Muralidhar","year":"2015","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.euo.2023.09.002","article-title":"Local therapy on clinically lymph node-positive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Yaow","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bju.13810","article-title":"Sentinel node biopsy for prostate cancer: report from a consensus panel meeting","volume":"120","author":"van der Poel","year":"2017","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.prnil.2025.02.001_bib57","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/diagnostics13152543","article-title":"Sentinel lymph node biopsy in prostate cancer: an overview of diagnostic performance, oncological outcomes, safety, and feasibility","volume":"13","author":"Rossin","year":"2023","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.juro.2015.01.008","article-title":"Intraoperative fluorescence imaging for detection of sentinel lymph nodes and lymphatic vessels during open prostatectomy using indocyanine green","volume":"194","author":"Yuen","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.02.001_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.931867","article-title":"Sentinel lymph node biopsy in prostate cancer patients: results from an injection technique targeting the index lesion in the prostate gland","volume":"9","author":"Fumad\u00f3","year":"2022","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib60","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-021-05580-0","article-title":"The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection","volume":"49","author":"Wit","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.prnil.2025.02.001_bib61","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2016.09.007","article-title":"Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy","volume":"71","author":"Wit","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/JU.0000000000003043","article-title":"Radioisotope-guided lymphadenectomy for pelvic lymph node staging in patients with intermediate- and high-risk prostate cancer (the prospective SENTINELLE study)","volume":"209","author":"Lannes","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Albo","year":"2019","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.prnil.2025.02.001_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112696","article-title":"Current status and future perspective on the management of lymph node-positive prostate cancer after radical prostatectomy","volume":"14","author":"Shiota","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12894-024-01448-1","article-title":"Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique","volume":"24","author":"Albo","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.prnil.2025.02.001_bib66","article-title":"Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?","author":"Roberts","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11701-013-0439-7","article-title":"Current status of pelvic lymph node dissection in prostate cancer","volume":"8","author":"Aleksic","year":"2014","journal-title":"J Robot Surg"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib68","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0970-1591.163303","article-title":"Extended lymph node dissection in robotic radical prostatectomy: current status","volume":"32","author":"Chopra","year":"2016","journal-title":"Indian J Urol"},{"issue":"11","key":"10.1016\/j.prnil.2025.02.001_bib70","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2018.02.024","article-title":"More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes with salvage radiotherapy for rising prostate-specific antigen after surgery: a long-term, multi-institutional analysis","volume":"74","author":"Fossati","year":"2018","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.prnil.2025.02.001_bib72","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.prnil.2025.02.001_bib73","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.prnil.2025.02.001_bib74","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.prnil.2025.02.001_bib75","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.prnil.2025.02.001_bib76","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1470-2045(21)00242-4","article-title":"Elective nodal radiotherapy in prostate cancer","volume":"22","author":"De","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10162","key":"10.1016\/j.prnil.2025.02.001_bib77","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib78","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00066-023-02129-y","article-title":"Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer-long-term data from the prospective PLATIN-2 trial","volume":"200","author":"Fink","year":"2024","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib79","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.prnil.2025.02.001_bib80","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.prnil.2025.02.001_bib81","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib82","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib83","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data Network meta-analysis from the MARCAP consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.prnil.2025.02.001_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.prnil.2025.02.001_bib85","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.prnil.2025.02.001_bib86","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.prnil.2025.02.001_bib87","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.prnil.2025.02.001_bib88","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10323","key":"10.1016\/j.prnil.2025.02.001_bib89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/JU.0000000000003518","article-title":"A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer","volume":"210","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euo.2022.12.001","article-title":"Prostate-specific membrane antigen-radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced prostate cancer with regional lymph node metastases","volume":"6","author":"Lunger","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.123.266495","article-title":"Prostate-specific membrane antigen-targeted radioguided pelvic lymph node dissection in newly diagnosed prostate cancer patients with a suspicion of locoregional lymph node metastases: the DETECT trial","volume":"65","author":"Schilham","year":"2024","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.prnil.2025.02.001_bib94","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/bc2002715","article-title":"Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate","volume":"22","author":"Nakajima","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.prnil.2025.02.001_bib95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7150\/thno.11918","article-title":"Triple-modal imaging of magnetically-targeted nanocapsules in solid tumours in vivo","volume":"6","author":"Bai","year":"2016","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.prnil.2025.02.001_bib96","first-page":"1","article-title":"Revolutionizing (robot-assisted) laparoscopic gamma tracing using a drop-in gamma probe technology","volume":"6","author":"van Oosterom","year":"2016","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.prnil.2025.02.001_bib97","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","article-title":"(99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer","volume":"75","author":"Maurer","year":"2019","journal-title":"Eur Urol"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:30:21Z","timestamp":1757543421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2287888225000054"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.02.001","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pelvic lymph node management in prostate cancer: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}